A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2023-08-11
- Completion
- 2024-02-28
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs Povorcitinib 15 mg; p = 0.0061; Odds Ratio (OR) 7.1 (95% CI 1.6 to 45.4); Regression, Logistic NCT05061693 ↗
release “The Phase 2, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of povorcitinib in participants with PN met its primary endpoint.” incyte.com ↗
release “study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis” incyte.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Povorcitinib | Small molecule | — | Oral |